SCHEDULE: EcoR1 Capital Discloses 9.9% Stake in Eloxx Pharma

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Summary

• EcoR1 Capital, LLC, its affiliate EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have reported a combined beneficial ownership of 403,586 shares of Eloxx Pharmaceuticals, Inc. common stock.
• The reported stake represents 9.9% of the company's outstanding common stock, calculated based on 4,036,314 shares outstanding following a June 9, 2026, securities offering.
• The holdings include 400,000 shares of common stock and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation.
• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it confirms continued institutional backing from a specialized healthcare investor following a recent capital raise.

Positives

• Institutional investor EcoR1 Capital has demonstrated significant confidence in the company by maintaining a 9.9% stake.
• The investment follows a recent capital raise by the issuer, suggesting continued institutional support for the company's financial position.

Negatives

• The reporting persons have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest, which is standard but highlights the nature of the investment vehicle.

Risks

• The investment is subject to a 9.99% beneficial ownership limitation, which restricts the ability of the reporting persons to increase their stake beyond this threshold without further regulatory filings or adjustments.
• The value of the investment is tied to the performance of Eloxx Pharmaceuticals, which is subject to the inherent risks of the pharmaceutical and biotechnology industry.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the reporting persons' intent to hold the securities in the ordinary course of business without seeking control.

Industry Context

StockSavvy.ai notes that institutional filings like this are common in the biotech sector, where specialized funds like EcoR1 Capital often take significant positions in small-cap pharmaceutical companies following capital raises to support clinical development pipelines.

Comparison to Industry Standards

• The 9.9% ownership stake is a standard threshold for institutional investors to maintain visibility while avoiding the more stringent reporting requirements associated with exceeding 10% or seeking active control.
• The use of pre-funded warrants is a common mechanism in biotech financing to allow investors to participate in offerings while managing beneficial ownership caps.

Stakeholder Impact

• Shareholders may view the continued support of a specialized institutional investor as a vote of confidence in the company's long-term prospects.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Keywords

Eloxx Pharmaceuticals, EcoR1 Capital, Schedule 13G, Oleg Nodelman, Biotech Investment, Institutional Ownership